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Everywhere in the world, it has been a major challenge to
properly protect inventions and other innovation-oriented
achievements in the fields of Life Sciences and Biotechnol-
ogy. Many aspects make these fields different and probably
harder to protect then general inventions on more tradi-
tional fields, such as mechanics or chemistry.
First, there are several ethical considerations, which have
been taken into account by legislators and judges every-
where. The appropriation of knowledge related to living
forms is sometimes seen as illegitimate, particularly that
related to the human body. Some legislations ban patents
in those fields explicitly. In other cases, courts may rule
them unlawful based on ethical considerations not directly
linked to any of the traditional patentability criteria. In
Brazil, law takes into consideration the rights of traditional
peoples on their traditional knowledge, and even on the
knowledge that may be developed from genetic resources
assumed to belong to traditional communities. This
requirements, particularly when they are difficult to
accomplish with as they are in Brazil, may stand also in
the field of ethical obstacles to knowledge appropriation
and commercialization.
A second source of uncertainty in the protection of
intellectual assets in those fields has to do with the use of
the flexibilities present in the Treaty on Trade-Related
Intellectual Property Aspects, generally referred to as
“TRIPS”. That treaty requires that patents be granted in
every technology field but in the field of Life Sciences.
With the exemption of genetically modified microorgan-
isms (autonomous, cells not included), living forms may
be put out of the general rules for patent granting, and
even be non-patentable at all, as it happens in Brazil and
in many developing countries.
Last, but not least, the application of the patentability
criteria itself for life forms may be trick, leading to conflic-
tive decisions on courts, which may only be pacified in the
highest level, as happened recently in the United States.
There are several ways to address the theme of ade-
quate or proper protection. The best approaches, in my
opinion, are the ones, which correlate objective and well
defined ways of protection to rates or speeds of knowl-
edge disseminations and innovation. Such approaches
are applied transversally, among countries or jurisdic-
tions, and may be insightful provided the sample does
not comprise countries where jurisprudence on Life-
Scieces and biotech patents is not consolidated yet.
Indeed, one of the worst things in terms of the impact of
patent systems on innovation seem to be the insufficient
consolidation of the understanding of the laws by the
courts. Probably that is the reason why many countries
follow the North-American example and create specialized
courts for IP matters, together with a continuous effort in
order to better describe in law the criteria for obtaining a
patent. Ethical considerations, for their inherent interpre-
tative nature, probably add to law uncertainty.
Brazil clearly stands in such a bad situation. Several laws
rule the appropriation of knowledge and the patentability
on Biotech/Biodiversity areas, there is no clear way to ful-
fill all requirements regarding traditional knowledge,
genetic resource definition is unclear and ownership on it
is subsequently problematic, as well as on the knowledge
which can be developed from it and on the products thus
developed. ANVISA “anuência” adds the final touch to
uncertainty on those patents when they relate to pharma-
ceutical products. The result is uncertainty and low invest-
ment in all fields related to the Brazilian Biodiversity, and
to any pharmaceutical oriented patent. The contradiction
between the enormous potential for innovation coming
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from the spectacular Brazilian Biodiversity and the low
rate of product development and patenting may be enough
to demonstrate that such uncertainty is clearly detrimental
for innovation.
When a country chooses not to protect a particular
field of technology knowledge, it clearly avoids invest-
ments in that field. It is not clear why Brazilian legisla-
tors have decided to ban from patentability insulated
natural substances with a known and well defined
industrial application. Some say it was due to a percep-
tion that there was no endogenous technology capacity,
which would be necessary to write the patens and
negotiate them. If this is really the case, maybe it is now
time to reconsider, not only in Brazil, but also in the
countries which have not adopted such protections for
the sake of providing no more than the minimum
requirements of TRIPS. Of course, minimal require-
ments are minimal, they are a floor and can never be
imagined as a ceiling, as this would confine legislation
to the standards established internationally and prevent
the country legislators to evaluate and decide with
sovereignty the ways the knowledge about the country
biodiversity and the results of research on Biotech and
Life Sciences should be protected.
In the international comparison, the United States
seems to offer adequate conditions for Biotech, to which
their patent system helps for sure. Nonetheless, even
there some uncertainty results from court decisions,
especially when related to genes. This probably suggests
that the international community might develop some
kind of “sui generis” protection system for segments of
genetic sequences with well-defined function and poten-
tial industrial application or use.
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